Spero Therapeutics secures $105 million royalty-backed financing from Healthcare Royalty (KKR)

Healthcare Royalty
Spero Therapeutics, Inc.

Healthcare Royalty

HCRX

0.00

Spero Therapeutics, Inc.

SPRO

0.00
  • Spero Therapeutics entered a $105 million non-recourse, non-dilutive royalty financing with affiliates of Healthcare Royalty, a KKR business.
  • Healthcare Royalty receives a portion of future Utebzi milestone and royalty payments owed by GSK until the loan balance is repaid.
  • Quarterly principal and interest payments come solely from the GSK payment stream tied to Utebzi sales.
  • Following repayment, Spero retains 35% of subsequent GSK payments related to Utebzi sales.
  • Proceeds fund Phase 2 development of SP001; cash runway guidance extended into the second half of 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140602PRIMZONEFULLFEED9761288) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.